Inhibition of JNK by a peptide inhibitor reduces traumatic brain injury-induced tauopathy in transgenic mice

Journal of Neuropathology and Experimental Neurology

Volumn 71, Issue 2, 2012, Pages 116-129

  Tran, Hien T ^a   Sanchez, Laura ^a   Brody, David L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

c Jun N terminal kinase; Controlled cortical impact; D JNKi1; Kinase; Phosphorylation; Tau; Traumatic brain injury

Indexed keywords

BML E1384; BML EI355; BML EI384; PHOSPHOPROTEIN PHOSPHATASE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TAUOPATHY; TRANSGENIC MOUSE; TRAUMATIC BRAIN INJURY; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN INJURIES; CEREBRAL CORTEX; DISABILITY EVALUATION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; PEPTIDES; PHOSPHORYLATION; PRESENILIN-1; SEVERITY OF ILLNESS INDEX; TAU PROTEINS; TAUOPATHIES;

EID: 84856065447     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3182456aed     Document Type: Article

References (97)

1. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007;8: 663-72 (Pubitemid 47283144)
2. Ikonomovic MD, Uryu K, Abrahamson EE, et al. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol 2004;190:192-203 (Pubitemid 39335718)
3. Uryu K, Chen XH, Martinez D, et al. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol 2007;208:185-92 (Pubitemid 350101496)
4. Johnson VE, Stewart W, Smith DH. Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol epub 2011;12
5. Corsellis JA. Boxing and the brain. Br Med J 1989;298:105-9 (Pubitemid 19032942)
6. Geddes JF, Vowles GH, Nicoll JA, et al. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol 1999;98:171-78 (Pubitemid 29355550)
7. Geddes JF, Vowles GH, Robinson SF, et al. Neurofibrillary tangles, but not Alzheimer-type pathology, in a young boxer. Neuropathol Appl Neurobiol 1996;22:12-16 (Pubitemid 26055829)
8. McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in athletes: Progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009;68:709-35
9. Roberts GW, Allsop D, Bruton C. The occult aftermath of boxing. J Neurol Neurosurg Psychiatry 1990;53:373-78 (Pubitemid 20173271)
10. Schmidt ML, Zhukareva V, Newell KL, et al. Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease. Acta Neuropathol 2001;101:518-24 (Pubitemid 32600142)
11. Tokuda T, Ikeda S, Yanagisawa N, et al. Reexamination of ex-boxers' brains using immunohistochemistry with antibodies to amyloid betaprotein and tau protein. Acta Neuropathol 1991;82:280-85
12. Anderton BH, Callahan L, Coleman P, et al. Dendritic changes in Alzheimer's disease and factors that may underlie these changes. Prog Neurobiol 1998;55:595-609 (Pubitemid 28293583)
13. Braak E, Braak H, Mandelkow EM. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 1994;87:554-67 (Pubitemid 24158408)
14. Drechsel DN, Hyman AA, Cobb MH, et al. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 1992;3:1141-54 (Pubitemid 23088964)
15. Alonso AC, Zaidi T, Grundke-Iqbal I, et al. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 1994;91:5562-66 (Pubitemid 24174368)
16. Bramblett GT, Goedert M, Jakes R, et al. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993;10:1089-99 (Pubitemid 23194399)
17. Merrick SE, Trojanowski JQ, Lee VM. Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons. J Neurosci 1997;17:5726-37 (Pubitemid 27310488)
18. Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 2005;1739:240-50 (Pubitemid 40021808)
19. Ballatore C, Brunden KR, Piscitelli F, et al. Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation. J Med Chem 2010;53:3739-47
20. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 2009;8:783-93
21. Noble W, Olm V, Takata K, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003;38:555-65 (Pubitemid 36645031)
22. Patrick GN, Zukerberg L, Nikolic M, et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999; 402:615-22 (Pubitemid 129516324)
23. Tseng HC, Zhou Y, Shen Y, et al. A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett 2002;523:58-62 (Pubitemid 34786058)
24. Hernandez F, Borrell J, Guaza C, et al. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 2002;83:1529-33 (Pubitemid 35477491)
25. Lucas JJ, Hernandez F, Gomez-Ramos P, et al. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. The EMBO J 2001;20:27-39 (Pubitemid 32099099)
26. Gong CX, Shaikh S, Wang JZ, et al. Phosphatase activity toward abnormally phosphorylated tau: Decrease in Alzheimer disease brain. J Neurochem 1995;65:732-38
27. Gong CX, Singh TJ, Grundke-Iqbal I, et al. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 1993;61:921-27 (Pubitemid 23241228)
28. Kins S, Crameri A, Evans DR, et al. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem 2001;276:38193-200
29. Litersky JM, Johnson GV. Phosphorylation by cAMP-dependent protein kinase inhibits the degradation of tau by calpain. J Biol Chem 1992;267: 1563-68
30. Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 2007;25:59-68 (Pubitemid 46098893)
31. Drewes G, Lichtenberg-Kraag B, Doring F, et al. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J 1992;11:2131-38
32. Goedert M, Cohen ES, Jakes R, et al. p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease [corrected]. FEBS Lett 1992;312:95-99
33. Buee-Scherrer V, Goedert M. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett 2002;515:151-54 (Pubitemid 34273915)
34. Goedert M, Hasegawa M, Jakes R, et al. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett 1997;409:57-62 (Pubitemid 27248567)
35. Yoshida H, Hastie CJ, McLauchlan H, et al. Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). J Neurochem 2004;90:352-58 (Pubitemid 38938221)
36. Vogel J, Anand VS, Ludwig B, et al. The JNK pathway amplifies and drives subcellular changes in tau phosphorylation. Neuropharmacology 2009;57:539-50
37. Tran HT, LaFerla FM, Holtzman DM, et al. Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-beta accumulation and independently accelerates the development of tau abnormalities. J Neurosci 2011;31:9513-25
38. Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 2003;39:409-21 (Pubitemid 36937044)
39. Brody DL, Mac Donald C, Kessens CC, et al. Electromagnetic controlled cortical impact device for precise, graded experimental traumatic brain injury. J Neurotrauma 2007;24:657-73 (Pubitemid 46996026)
40. Planel E, Miyasaka T, Launey T, et al. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: Implications for Alzheimer's disease. J Neurosci 2004;24:2401-11 (Pubitemid 38327953)
41. Cirrito JR, May PC, O'Dell MA, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 2003;23:8844-53 (Pubitemid 37210896)
42. Franklin KB, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. London, UK: Academic Press, 1997
43. Kim J, Castellano JM, Jiang H, et al. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 2009;64: 632-44
44. Mac Donald CL, Dikranian K, Song SK, et al. Detection of traumatic axonal injury with diffusion tensor imaging in a mouse model of traumatic brain injury. Exp Neurol 2007;205:116-31 (Pubitemid 46629058)
45. Bonny C, Oberson A, Negri S, et al. Cell-permeable peptide inhibitors of JNK: Novel blockers of beta-cell death. Diabetes 2001;50:77-82 (Pubitemid 32047984)
46. Borsello T, Clarke PG, Hirt L, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 2003;9:1180-86 (Pubitemid 37173703)
47. Borsello T, Croquelois K, Hornung JP, et al. N-methyl-D-aspartateY triggered neuronal death in organotypic hippocampal cultures is endocytic, autophagic and mediated by the c-Jun N-terminal kinase pathway. Eur J Neurosci 2003;18:473-85 (Pubitemid 37041099)
48. Barr RK, Kendrick TS, Bogoyevitch MA. Identification of the critical features of a small peptide inhibitor of JNK activity. J Biol Chem 2002; 277:10987-97 (Pubitemid 34952855)
49. Cruz JC, Tseng HC, Goldman JA, et al. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003;40:471-83 (Pubitemid 37494698)
50. Arendt T, Holzer M, Fruth R, et al. Phosphorylation of tau, Abetaformation, and apoptosis after in vivo inhibition of PP-1 and PP-2A. Neurobiol Aging 1998;19:3-13 (Pubitemid 28167790)
51. Litersky JM, Johnson GV, Jakes R, et al. Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem J 1996;316:655-60 (Pubitemid 26182167)
52. Robertson J, Loviny TL, Goedert M, et al. Phosphorylation of tau by cyclic-AMPYdependent protein kinase. Dementia 1993;4:256-63 (Pubitemid 23281686)
53. Sperber BR, Leight S, Goedert M, et al. Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett 1995;197:149-53
54. Virdee K, Yoshida H, Peak-Chew S, et al. Phosphorylation of human microtubule-associated protein tau by protein kinases of the AGC subfamily. FEBS Lett 2007;581:2657-62 (Pubitemid 46829108)
55. Adams JA, McGlone ML, Gibson R, et al. Phosphorylation modulates catalytic function and regulation in the cAMP-dependent protein kinase. Biochemistry 1995;34:2447-54
56. Smith CM, Radzio-Andzelm E, Madhusudan, et al. The catalytic subunit of cAMP-dependent protein kinase: Prototype for an extended network of communication. Prog Biophys Mol Biol 1999;71:313-41 (Pubitemid 29156305)
57. Anderson NG, Maller JL, Tonks NK, et al. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 1990;343:651-53
58. Lisnock J, Griffin P, Calaycay J, et al. Activation of JNK3 alpha 1 requires both MKK4 and MKK7: Kinetic characterization of in vitro phosphorylated JNK3 alpha 1. Biochemistry 2000;39:3141-48 (Pubitemid 30159421)
59. Wada T, Nakagawa K, Watanabe T, et al. Impaired synergistic activation of stress-activated protein kinase SAPK/JNK in mouse embryonic stem cells lacking SEK1/MKK4: Different contribution of SEK2/MKK7 isoforms to the synergistic activation. J Biol Chem 2001;276:30892-97
60. Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378: 785-89 (Pubitemid 26004411)
61. Wang JZ, Gong CX, Zaidi T, et al. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and-2B. J Biol Chem 1995;270:4854-60
62. Gong CX, Lidsky T, Wegiel J, et al. Phosphorylation of microtubuleassociated protein tau is regulated by protein phosphatase 2A in mammalian brain: Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem 2000;275:5535-44 (Pubitemid 30115189)
63. Geddes JF, Whitwell HL, Graham DI. Traumatic axonal injury: Practical issues for diagnosis in medicolegal cases. Neuropathol Appl Neurobiol 2000;26:105-16 (Pubitemid 30251383)
64. Gennarelli TA, Thibault LE, Adams JH, et al. Diffuse axonal injury and traumatic coma in the primate. Ann Neurol 1982;12:564-74 (Pubitemid 13250413)
65. Gentleman SM, Roberts GW, Gennarelli TA, et al. Axonal injury: A universal consequence of fatal closed head injury? Acta Neuropathol 1995;89:537-43
66. Smith DH, Meaney DF, Shull WH. Diffuse axonal injury in head trauma. J Head Trauma Rehab 2003;18:307-16 (Pubitemid 36899043)
67. Povlishock JT, Christman CW. The pathobiology of traumatically induced axonal injury in animals and humans: A review of current thoughts. J Neurotrauma 1995;12:555-64
68. Bhat RV, Shanley J, Correll MP, et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Nat Acad Sci USA 2000;97:11074-79
69. Hughes K, Nikolakaki E, Plyte SE, et al. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 1993;12: 803-8 (Pubitemid 23073729)
70. Leroy K, Boutajangout A, Authelet M, et al. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol 2002;103:91-99 (Pubitemid 36067485)
71. Hibi M, Lin A, Smeal T, et al. Identification of an oncoprotein-and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993;7:2135-48 (Pubitemid 23336140)
72. Graham DI, Gentleman SM, Lynch A, et al. Distribution of beta-amyloid protein in the brain following severe head injury. Neuropathol Appl Neurobiol 1995;21:27-34
73. Sherriff FE, Bridges LR, Gentleman SM, et al. Markers of axonal injury in post mortem human brain. Acta Neuropathol 1994;88:433-39 (Pubitemid 24331029)
74. Stone JR, Singleton RH, Povlishock JT. Antibodies to the C-terminus of the beta-amyloid precursor protein (APP): A site specific marker for the detection of traumatic axonal injury. Brain Res 2000;871:288-302 (Pubitemid 30433880)
75. Stone JR, Singleton RH, Povlishock JT. Intra-axonal neurofilament compaction does not evoke local axonal swelling in all traumatically injured axons. Exp Neurol 2001;172:320-31 (Pubitemid 34075081)
76. Johnson-Wood K, Lee M, Motter R, et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad USA 1997;94:1550-55
77. Colombo A, Repici M, Pesaresi M, et al. The TAT-JNK inhibitor peptide interferes with beta amyloid protein stability. Cell Death Differ 2007;14: 1845-48 (Pubitemid 47423652)
78. Greenberg SG, Davies P, Schein JD, et al. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem 1992;267:564-69
79. Otvos L Jr, Feiner L, Lang E, et al. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 1994;39:669-73
80. Reynolds CH, Utton MA, Gibb GM, et al. Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein. J Neurochem 1997;68: 1736-44 (Pubitemid 27133085)
81. Averill S, Delcroix JD, Michael GJ, et al. Nerve growth factor modulates the activation status and fast axonal transport of ERK 1/2 in adult nociceptive neurones. Mol Cell Neurosci 2001;18:183-96 (Pubitemid 32846527)
82. Middlemas A, Delcroix JD, Sayers NM, et al. Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3. Brain 2003;126: 1671-82 (Pubitemid 36834943)
83. Reynolds AJ, Hendry IA, Bartlett SE. Anterograde and retrograde transport of active extracellular signalYregulated kinase 1 (ERK1) in the ligated rat sciatic nerve. Neuroscience 2001;105:761-71 (Pubitemid 32769838)
84. Brunden KR, Zhang B, Carroll J, et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 2010;30:13861-66
85. Otani N, Nawashiro H, Fukui S, et al. Differential activation of mitogenactivated protein kinase pathways after traumatic brain injury in the rat hippocampus. J Cereb Blood Flow Metab 2002;22:327-34 (Pubitemid 34203060)
86. Ortolano F, Colombo A, Zanier ER, et al. c-Jun N-terminal kinase pathway activation in human and experimental cerebral contusion. J Neuropathol Exp Neurol 2009;68:964-71
87. Mori T, Wang X, Jung JC, et al. Mitogen-activated protein kinase inhibition in traumatic brain injury: In vitro and in vivo effects. J Cereb Blood Flow Met 2002;22:444-52 (Pubitemid 34273600)
88. Otani N, Nawashiro H, Fukui S, et al. Temporal and spatial profile of phosphorylated mitogenYactivated protein kinase pathways after lateral fluid percussion injury in the cortex of the rat brain. J Neurotrauma 2002; 19:1587-96 (Pubitemid 36026214)
89. Raghupathi R, Muir JK, Fulp CT, et al. Acute activation of mitogenactivated protein kinases following traumatic brain injury in the rat: Implications for posttraumatic cell death. Exp Neurol 2003;183:438-48 (Pubitemid 37205085)
90. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-69 (Pubitemid 32267078)
91. Silva RM, Kuan CY, Rakic P, et al. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: A new therapeutic target in Parkinson's disease. Mov Disord 2005;20:653-64 (Pubitemid 41051776)
92. Cavalli V, Kujala P, Klumperman J, et al. Sunday driver links axonal transport to damage signaling. J Cell Biol 2005;168:775-87 (Pubitemid 40328161)
93. Miller BR, Press C, Daniels RW, et al. A dual leucine kinase-dependent axon self-destruction program promotes Wallerian degeneration. Nat Neurosci 2009;12:387-89
94. Kanaan NM, Morfini GA, Lapointe NE, et al. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J Neurosci 2011;31:9858-68
95. Cohen TJ, Guo JL, Hurtado DE, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2011;2:252
96. Min SW, Cho SH, Zhou Y, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010;67:953-66
97. Gerdts J, Sasaki Y, Vohra B, et al. Image-based screening identifies novel roles for i{kappa}b kinase and glycogen synthase kinase 3 in axonal degeneration. J Biol Chem 2011;286:28011-18